These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 24479242

  • 1. Off-label promotion: government theories of prosecution and facts that drive them.
    Burroughs AD, Levy MC, Schwab GG, Paik Y.
    Food Drug Law J; 2010; 65(3):555-88. PubMed ID: 24479242
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Manufacturers' promotion of off-label drug use: implications for drug safety.
    Zieve A, Carome MA.
    Expert Opin Drug Saf; 2016 Sep; 15(9):1149-51. PubMed ID: 27145440
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L.
    Am J Law Med; 2014 Sep; 40(1):141-63. PubMed ID: 24844045
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA.
    Issue Brief Health Policy Track Serv; 2010 Jan 04; ():1-31. PubMed ID: 20217914
    [No Abstract] [Full Text] [Related]

  • 11. The future of off-label marketing regulations in the post-Sorrell era.
    Iraggi J.
    Seton Hall Law Rev; 2013 Jan 04; 43(3):1137-63. PubMed ID: 23802338
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Off-Label Marketing's Audiences: The 21st Century Cures Act and the Relaxation of Standards for Evidence-Based Therapeutic and Cost-Comparative Claims.
    Halabi SF.
    Am J Law Med; 2018 May 04; 44(2-3):181-196. PubMed ID: 30106659
    [No Abstract] [Full Text] [Related]

  • 14. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB, Yentzer BA, Feldman SR.
    Skin Therapy Lett; 2015 May 04; 20(3):1-4. PubMed ID: 26382556
    [Abstract] [Full Text] [Related]

  • 15. Evaluating promotional claims as false or misleading.
    Brushwood DB, Knox CA, Liu W, Jenkins KA.
    Am J Health Syst Pharm; 2013 Nov 01; 70(21):1941-4. PubMed ID: 24128969
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Origins of the prohibition against off-label promotion.
    Coleman TS.
    Food Drug Law J; 2014 Nov 01; 69(2):161-236, i. PubMed ID: 25163210
    [Abstract] [Full Text] [Related]

  • 18. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West.
    Issue Brief Health Policy Track Serv; 2011 Jan 03; ():1-39. PubMed ID: 21374841
    [No Abstract] [Full Text] [Related]

  • 19. The ban on "off-label" pharmaceutical promotion: constitutionally permissible prophylaxis against false or misleading commercial speech?
    Greenwood K.
    Am J Law Med; 2011 Jan 03; 37(2-3):278-98. PubMed ID: 21847882
    [Abstract] [Full Text] [Related]

  • 20. Major issues in marketing regulation.
    Pines WL.
    Food Drug Law J; 1997 Jan 03; 52(3):297-302. PubMed ID: 10343028
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.